Osteochondral Transplantation: Safety, Efficacy and Outcomes

Philip A. Davidson, MD Heiden Orthopaedics Park City, UT AANA Fall Meeting Nov. 2008





DISCLOSURE

No commercial relationship exists between the author and any entity relating to the topic of this presentation





Osteochondral Transplantation Perspective.....

- Focus on Allografts
- Effective
- Increasingly Popular
- Broadening Indications
- Growing Demand
- BUT.....
 - Great safety concerns
 - Limited Supply







Allograft Safety ...remember want LIVING cells for OCA

- Living chondroctyes
 - Produce matrix
- Problem:
 - Pathogen contamination
- Infection:
 - Donor transmission
 - Processing contamination







ALLOGRAFT SAFETY – OA GRAFTS

- Sterilization processes all cytotoxic
- Want to maximize cellular viability...but must ensure safety
- KEYS:
 - Donor screening
 - Aseptic harvesting
 - Aseptic processing
 - Usage of antimicrobials







ALLOGRAFT ASSOCIATED INFECTION

- Bacterial:
 - Principally enteric
 - CDC analysis of AAI 2002
 - 37 infections
 - Gram negative rods; Clostridium; Enterococcus; Candida
- Viral:
 - Hepatitis; HIV; West Nile
 - Emerging: SARS; Monkey Pox; Chagas





Government Oversight and Policy

• FDA:

- Center for Biologics Evaluation and Research (CBER)
- Current Good Tissue Practices (CGTP)
- <u>http://www.fda.gov/cber/gdlns/cgtpmanuf.htm</u>
- AAOS: formally recommends only using tissue from AATB approved and FDA-CGTP compliant tissue banks and suppliers





Fresh OCA vs. Fresh Stored OCA

- Historically Grafts were implanted in the days immediately following donor death (1st week)
 - Gross, Toronto
 - Convery, UCSD
- Fresh OCA no longer performed in USA because of safety AND these issues:
 - Medical-Legal
 - Practical

PHILDAVIDSONMD.com

Legislation









Fresh Stored Graft - Cellular Viability

- Viability is related principally to time between donor death and implantation
- Tissue maintained in controlled, nutrient environment before transplantation at 4°C
- Most commercial grafts in USA currently between 15 and 35 days

Chondrocyte viability vs. storage time



Williams S. K. et.al. J Bone Joint Surg 2003:85:2111-2120

HEIDENORTHO.COM



Prospective Evaluation of Prolonged Fresh Osteochondral Allograft Transplantation of the Femoral Condyle - Minimum 2-Year Follow-Up

P. C. McCulloch, MD*, R.W. Kang, M. H. Sobhy, MD, J. K. Hayden, MS and B. J. Cole, MD, MBA The American Journal of Sports Medicine 35:411-420 (2007)







Clinical, Histologic, and Radiographic Outcomes of Distal Femoral Resurfacing With Hypothermically Stored Osteoarticular Allografts

P. A. Davidson, D. W. Rivenburgh, P.E. Dawson, and R. Rozin Am. J. Sports Med., Jul 2007; 35: 1082 - 1090.









OA Graft Clinical Biopsy Study

- 10 second look, biopsy evaluations of massive OA Allografts Distal Femur
- MRI, Histologic and Clinical Eval
- Fresh Stored OA grafts







Demographics: Biopsy Study Group

- Primary diagnosis:
 - Trauma 4, Instability 2, OCD 4
- Mean recipient age : 33 yrs
- Mean donor age: 25 yrs
- Mean days between asystole and implantation: 36 days (min 28 days)
- Mean interval between implant and biopsy: 40 mos.
- Mean graft size: 6.2 cm²





Histologic Analysis

- Fluorescent microscopy using a triple bandpass filter equipped with a high speed CCD camera
 - Red dead, green live
 - Ethidium homodimer and calcein
- H & E; Safranin O; mod. Trichrome stains
- Cellular viability and cellular density evaluated





Results: IKDC Scores

- 0-100 point system
- Pre-op mean: 27 (range 9-55)
- Post-op mean: 79 (range 56-99)

Discussion

- Clinically, patients and grafts in this series and others have objectively done very well.
- Few attractive options for these young patients with advanced osteochondral disease
- Grafts appear durable over a short and long term.
- Ref- Gross, et. al.
 - > 20 year data on graft survival

Allograft Safety – What can you do?

- AAOS guidelines
- Want tissue bank fully compliant with CGTP and AATB
- Pre, intra and post op antibiotic prophylaxis
- Understand important considerations in graft viability, processing and handling
- Approach OCA holistically, addressing full spectrum of knee pathology

Future of OCA (It's here!!)

- Juvenile OCA
 - Minced cartilage mixed with substrate
- Combination products involving bioengineered elements and OCA
- Allogeneic chondrocytes on scaffolds
- Enhanced storage and processing may increase viability in storage

Thank you pdavidson@heidenortho.com

